TETERBORO, N.J., Jan. 7 /PRNewswire/ -- Quest Diagnostics Incorporated
(NYSE: DGX), the nation's leading provider of diagnostic testing, information
and services, announced that Kenneth W. Freeman, Chairman and Chief Executive
Officer, is scheduled to speak at the JPMorgan H&Q 20th Annual Healthcare
Conference on Tuesday, January 8, 2002, at the Westin St. Francis Hotel in San
Francisco. The Quest Diagnostics presentation is scheduled to begin at 8:30
a.m. Pacific Time. The conference is being webcast live and can be accessed
on the Internet at:
http://php4.eventsdigital.com/events/jpmhq/healthcare2002/index.html. A
replay of the webcast will be available for 60 days following the conference.
Quest Diagnostics is scheduled to release financial results for the fourth
quarter ended December 31, 2001, after the close of the stock market on
January 28, 2002. The company is currently in a "quiet" period and is
scheduled to discuss results for the fourth quarter during a conference call
on January 29 at 8:00 a.m. Eastern Time. To hear a simulcast of the call over
the Internet or a replay, registered analysts may access StreetEvents at:
http://www.streetevents.com; and all others may access the Quest Diagnostics
website at: http://www.questdiagnostics.com. In addition, a replay of the
call will be available from 10 a.m. on January 29 through 5 p.m. on January 31
to investors in the U.S. by dialing 800-754-7906. Investors outside the U.S.
may dial 402-220-0366. No password is required for either number.
Quest Diagnostics is the nation's leading provider of diagnostic testing,
information and services with $3.4 billion in annual revenues. The company's
diagnostic testing yields information that enables health care professionals
and consumers to make better decisions to improve health. Quest Diagnostics
offers patients and physicians the broadest access to diagnostic testing
services through its national network of approximately 30 full-service
laboratories, 150 rapid response laboratories and more than 1,300 patient
service centers, where specimens are collected. Quest Diagnostics is the
leading provider of esoteric testing, including gene-based testing, and is the
leader in routine medical testing, drugs of abuse testing, and
non-hospital-based anatomic pathology testing. Quest Diagnostics empowers
health care organizations and clinicians with state-of-the-art connectivity
solutions that improve practice management. Through partnerships with
pharmaceutical, biotechnology and information technology companies, Quest
Diagnostics provides support to help speed the development of health care
insights and new therapeutics. Additional company information can be found on
the Internet at: http://www.questdiagnostics.com.
The statements in this press release which are not historical facts or
information may be forward-looking statements. These forward-looking
statements involve risks and uncertainties that could cause the outcome to be
materially different. Certain of these risks and uncertainties are listed in
the Quest Diagnostics Incorporated 2000 Form 10-K and subsequent filings.
SOURCE Quest Diagnostics Incorporated
 back to top
Related links:
http://www.questdiagnostics.com
CONTACT:
Media - Gary Samuels, +1-201-393-5700,
Investors - Cathy Doherty, +1-201-393-5030, both of Quest
Diagnostics Incorporated
|
